The myths that drive therapeutic inertia in multiple sclerosis: a cost-effectiveness analysis of high-efficacy drugs in Brazil-Reference-Cited by-同舟云学术

The myths that drive therapeutic inertia in multiple sclerosis: a cost-effectiveness analysis of high-efficacy drugs in Brazil

Published:2024-01 Issue:01 Volume:82 Page:001-002
ISSN:0004-282X
Container-title:Arquivos de Neuro-Psiquiatria
language:en
Short-container-title:Arq Neuropsiquiatr

Author:

Pipek Leonardo Zumerkorn¹^ORCID,Mahler João Vitor²^ORCID,Nascimento Rafaela Farias Vidigal³^ORCID,Becker Jefferson⁴^ORCID,Apóstolos-Pereira Samira Luísa¹^ORCID,Adoni Tarso¹^ORCID,Silva Guilherme Diogo¹^ORCID,Callegaro Dagoberto¹^ORCID,

Affiliation:

1. Universidade de São Paulo, Hospital das Clínicas, Departamento de Neurologia, São Paulo SP, Brazil.

2. Universidade de São Paulo, Faculdade de Medicina, São Paulo SP, Brazil.

3. Faculdade de Medicina do ABC, Centro Universitário, Santo André SP, Brazil.

4. Pontifícia Universidade Católica do Rio Grande do Sul, Hospital São Lucas, Departamento de Neurologia, Porto Alegre RS, Brazil.

Publisher

Georg Thieme Verlag KG

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0044-1779036.pdf

Reference4 articles.

1. The clinical-radiological paradox in multiple sclerosis: myth or truth?;A Hartmann;Arq Neuropsiquiatr,2023

2. Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis;L Z Pipek;Mult Scler Relat Disord,2023

3. Burden and cost of multiple sclerosis in Brazil;G Kobelt;PLoS One,2019

4. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial;A Svenningsson;Lancet Neurol,2022